Research aimed at finding Fragile X syndrome treatments is exploding. Why are so many pharmaceutical and biotech companies investing in this orphan indication? FRAXA chief scientific officer Dr. Michael Tranfaglia explains the many reasons Fragile X is such a hot topic.
FRAXA Research Foundation – Finding a Cure for Fragile X Syndrome
Accelerating Fragile X Research for Effective Treatments
